Pharmacists in the pharmacovigilance system
Issue:
5
Year:
2024
Introduction. In accordance with the rules of the GVP EAEU, good pharmacy practice and the national legislation of Russia, pharmacy organizations, as subjects of circulation of medicines, must collect and send reports of adverse reactions to the authorized body about the information they receive from patients.
Objective. Studying the level of knowledge and practical skills, as well as the opinions of pharmacy workers about the pharmacovigilance system in order to develop practical management solutions to increase the participation of the pharmacy link in the pharmacovigilance system.
Material and methods. Questionnaire method, descriptive statistics, non-prametric statistics according to the Kendal and Spearman test.
Results. A Google link to the questionnaire was sent to 150 pharmacy ratings to complete. Employees of the retail pharmaceutical sector of the Republic of North Ossetia (Alania) took part in the questionnaire. 105 valid completed questionnaires were received. The return rate of the questionnaire is 70%. 62% of the respondents answered that an AR notification should be reported only if there is a proven causal relationship between taking the drug and the resulting AR; 30% believe that it should be sent if a causal relationship is suspected; 1% in free time from other duties; 7% – believe that it is necessary to report if the buyer asks for it. 39 (37,1%) of respondents answered that the decisive factor preventing them from filling out notices is the too long filing procedure, 56 (53,4%) of respondents referred to the lack of time for this procedure, 10 (9,5%) respondents – on the lack of meaning in this activity. The main stimulating factor that, according to the respondents, can motivate the receipt of notices is material.
Conclusion. The study revealed an increase in the competencies of pharmacy workers and the search for solutions to motivate them to increase their involvement in the pharmacovigilance system.
Keywords:
Adverse drug reactions
drug safety; pharmacist; pharmacovigilance
post marketing surveillance
References:
- Radecka A., Loughlin L., Foy M. et al. Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint Action. Drug Saf. 2018; 41: 1285–302. DOI: 10.1007/s40264-018-0708-5.
- Munir Pirmohamed, Sally James, Shaun Meakin, Chris Green, Andrew K. Scott, Thomas J. Walley, Keith Farrar, B. Kevin Park, Alasdair M. Breckenridge Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004; 329 (7456): 15–9. DOI: 10.1136/bmj.329.7456.15
- Bouvy J.C., De Bruin M.L. & Koopmanschap M.A. Epidemiology of Adverse Drug Reactions in Europe: A Review of Recent Observational Studies. Drug Saf. 2015; 38: 437–53. https://doi.org/10.1007/s40264-015-0281-0
- Paul Beninger, Signal Management in Pharmacovigilance: A Review of Activities and Case Studies. Clinical Therapeutics. 2020; 6 (42): 1110–29. DOI: 10.1016/j.clinthera.2020.03.018.
- Кудрявцева Е.М., Горелов К.В. Проведение фармаконадзора в медицинских организациях. Вестник Росздравнадзора. 2021; 2: 53–7. [Kudryavceva E.M., Gorelov K.V. Provedenie farmakonadzora v medicinskih organizaciyah. Vestnik Roszdravnadzora. 2021; 2: 53–7 (in Russian)]
- Peters T., Soanes N., Abbas M., Ahmad J., Delumeau J.C., Herrero-Martinez E., Paramananda M., Piper J., Smail-Aoudia F., van der Spuij W., Veizovic T., Winstanley G. EFPIA International Pharmacovigilance Group. Effective Pharmacovigilance System Development: EFPIA-IPVG Consensus Recommendations. Drug Saf. 2021; 44 (1): 17–28. DOI: 10.1007/s40264-020-01008-0.
- Hughes M.L., Weiss M. Adverse drug reaction reporting by community pharmacists-The barriers and facilitators. Pharmacoepidemiol Drug Saf. 2019; 28 (12): 1552–9. DOI: 10.1002/pds.4800. Epub 2019 May 27. PMID: 31131966.
- Крашенинников А.Е., Романов Б.К., Сафиуллин Р.С., Шестаков Н.В. Необходимость формирования диалектического мышления у работников аптечных организаций для повышения их эффективности в системе фармаконадзора. Безопасность и риск фармакотерапии. 2022; 10 (3): 208–17. [Krasheninnikov A.E., Romanov B.K., Safiullin R.S., SHestakov N.V. Neobhodimost' formirovaniya dialekticheskogo myshleniya u rabotnikov aptechnyh organizacij dlya povysheniya ih effektivnosti v sisteme farmakonadzora. Bezopasnost' i risk farmakoterapii. 2022; 10 (3): 208–17. https://doi.org/10.30895/2312-7821-2022-10-3-208-217 (in Russian)]
- De Smet P.A. Clinical risk management of herb-drug interactions. Br. J. Clin. Pharmacol. 2007; 63 (3): 258–67. DOI: 10.1111/j.1365-2125.2006.02797.x.
- Paut Kusturica M., Tomas A., Rašković A., Gigov S., Crnobrnja V., Jevtić M., Stilinović N. Community pharmacists' challenges regarding adverse drug reaction reporting: a cross-sectional study. Curr Med Res Opin. 2022; 38 (7): 1229–36. DOI: 10.1080/03007995.2022.2070380.
- Аносов И.С. Изучение факторов, влияющих на фармацевтическую безопасность при отпуске лекарственных препаратов. Вестник Российского университета дружбы народов. Серия Медицина. 2013; 6: 10–3. [Anosov I.S. Izuchenie faktorov, vliyayushchih na farmacevticheskuyu bezopasnost' pri otpuske lekarstvennyh preparatov. Vestnik Rossijskogo universiteta druzhby narodov. Seriya Medicina. 2013; 6: 10–3 (in Russian)]
- Hajj A., Hallit S., Ramia E., Salameh P. Order of Pharmacists Scientific Committee – Medication Safety Subcommittee. Medication safety knowledge, attitudes and practices among community pharmacists in Lebanon. Curr Med Res Opin. 2018; 34 (1): 149–56. DOI: 10.1080/03007995.2017.1361916.
- Al-Worafi Y.M., Kassab Y.W., Alseragi W.M., Almutairi M.S., Ahmed A., Ming L.C., Alkhoshaiban A.S., Hadi M.A. Pharmacovigilance and adverse drug reaction reporting: a perspective of community pharmacists and pharmacy technicians in Sana'a, Yemen. Ther Clin Risk Manag. 2017; 13: 1175–81. DOI: 10.2147/TCRM.S140674.
- Kopciuch D., Zaprutko T., Paczkowska A., Ratajczak P., Zielińska-Tomczak Ł., Kus K., Nowakowska E. Safety of medicines-Pharmacists' knowledge, practice, and attitudes toward pharmacovigilance and adverse drug reactions reporting process. Pharmacoepidemiol Drug Saf. 2019; 28 (12): 1543–51. DOI: 10.1002/pds.4792.
- Ferreira-da-Silva R., Alves J.M., Vieira C., Silva A.M., Marques J., Morato M., Polónia J.J., Ribeiro-Vaz I. Motivation and Knowledge of Portuguese Community Pharmacists Towards the Reporting of Suspected Adverse Reactions to Medicines: A Cross-Sectional Survey. J. Community Health. 2023; 48 (2): 295–308. DOI: 10.1007/s10900-022-01168-3.